Exchange: NYSE
Industry: Pharmaceuticals & Biotechnology
Last Trade: 4:00 PM ET 4/5/2013
Last 10 Quotes:
What's This?
| Fiscal Q4 Ending 12/12 |
Fiscal Q3 Ending 09/12 |
Fiscal Q2 Ending 06/12 |
Fiscal Q1 Ending 03/12 |
Fiscal Q4 Ending 12/11 |
|
Sales/Revenue |
4,191,000 | 3,736,000 | 4,443,000 | 5,251,000 | 5,454,000 |
Cost of Goods Sold (COGS) incl. D&A |
1,075,000 | 987,000 | 1,098,000 | 1,303,000 | 1,352,000 |
COGS excluding D&A |
876,000 | 697,000 | 906,000 | 1,117,000 | 1,145,000 |
Depreciation & Amortization Expense |
199,000 | 290,000 | 192,000 | 186,000 | 207,000 |
Gross Income |
3,116,000 | 2,749,000 | 3,345,000 | 3,948,000 | 4,102,000 |
SG&A Expense |
2,437,000 | 2,189,000 | 2,145,000 | 2,105,000 | 2,499,000 |
Research & Development |
1,082,000 | 951,000 | 917,000 | 909,000 | 1,008,000 |
Other SG&A |
1,355,000 | 1,238,000 | 1,228,000 | 1,196,000 | 1,491,000 |
Other Operating Expense |
0 | 0 | 0 | 0 | 0 |
Unusual Expense |
210,000 | 1,963,000 | 235,000 | -81,000 | 133,000 |
Non Operating Income/Expense |
62,000 | 125,000 | 82,000 | 88,000 | 100,000 |
Equity in Affiliates (Pretax) |
33,000 | 40,000 | 0 | 0 | 0 |
Interest Expense |
51,000 | 48,000 | 41,000 | 42,000 | 42,000 |
Gross Interest Expense |
51,000 | 48,000 | 41,000 | 42,000 | 42,000 |
Pretax Income |
513,000 | -1,259,000 | 1,006,000 | 1,970,000 | 1,528,000 |
Income Tax |
-411,000 | -546,000 | 251,000 | 545,000 | 363,000 |
Equity in Affiliates |
0 | 0 | 53,000 | 57,000 | 66,000 |
Consolidated Net Income |
924,000 | -713,000 | 808,000 | 1,481,000 | 1,229,000 |
Minority Interest Expense |
-1,000 | -2,000 | 163,000 | 381,000 | 379,000 |
Net Income |
925,000 | -711,000 | 645,000 | 1,100,000 | 850,000 |
Extraordinaries & Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Extra Items & Gain/Loss Sale Of Assets |
0 | 0 | 0 | 0 | 0 |
Cumulative Effect - Accounting Chg |
0 | 0 | 0 | 0 | 0 |
Discontinued Operations |
0 | 0 | 0 | 0 | 0 |
Net Income After Extraordinaries |
925,000 | -711,000 | 645,000 | 1,100,000 | 850,000 |
Preferred Dividends |
0 | 0 | 0 | 0 | 0 |
Net Income available to Common |
925,000 | -711,000 | 645,000 | 1,100,000 | 850,000 |
Operational EPS |
0.64 | 0.40 | 0.48 | 0.61 | 0.55 |
EPS (basic) |
0.56 | -0.43 | 0.38 | 0.65 | 0.50 |
EBITDA |
878,000 | 850,000 | 1,392,000 | 2,029,000 | 1,810,000 |
Depreciation & Amortization Expense |
199,000 | 290,000 | 192,000 | 186,000 | 207,000 |
Common Shares Outstanding |
1,688,000 | 1,666,000 | 1,701,000 | 1,706,000 | 1,717,000 |
Basic Shares Outstanding |
1,670,000 | 1,666,000 | 1,683,000 | 1,687,000 | 1,700,000 |
Diluted Shares Outstanding |
1,688,000 | 1,666,000 | 1,701,000 | 1,706,000 | 1,717,000 |
Diluted EPS after Extraordinary Items |
0.55 | -0.43 | 0.38 | 0.64 | 0.50 |
Discont. Operations Per Share |
0 | 0 | 0 | 0 | 0 |
Continued operations EPS |
0.55 | -0.43 | 0.38 | 0.64 | 0.50 |
*Figures in thousands of U.S. Dollars except shares outstanding.
